Tharimmune, Inc. Presents Positive Phase 1 Data for Lead Candidate TH104 at ACG 2024 Meeting
Development of TH104
Tharimmune, Inc. recently announced the positive results from the Phase 1 trial of TH104, the Company’s lead candidate for moderate-to-severe pruritus in chronic liver disease. The trial demonstrated that TH104 showed no opioid withdrawal effects, reinforcing its safety profile. Furthermore, TH104 was well tolerated with no unexpected treatment-emergent adverse events, which supports its further clinical development.
Phase 1 Trial Details
The Phase 1 trial of TH104 was a single-dose, single-center, open-label, randomized study conducted in two cohorts of patients with chronic liver disease. The trial focused on a transmucosal buccal film formulation of TH104, with promising results.
Future Prospects for TH104
Tharimmune, Inc. anticipates releasing Phase 2 topline data for chronic pruritus in primary biliary cholangitis (PBC) patients in 2025. These results will provide further insight into the efficacy and safety of TH104 in treating pruritus associated with liver diseases.
Impact on Individuals
As an individual, the development of TH104 could offer a potential new treatment option for those suffering from chronic liver disease-related pruritus. The positive Phase 1 data suggests that TH104 may be a safe and effective therapy, which could improve the quality of life for patients dealing with this challenging symptom.
Impact on the World
On a broader scale, the success of TH104 could have significant implications for the medical community and the pharmaceutical industry. If TH104 proves to be a successful treatment for pruritus in chronic liver disease, it could potentially pave the way for innovative therapies in inflammation and immunology, benefiting patients worldwide.
Conclusion
The positive Phase 1 data presented by Tharimmune, Inc. for TH104 at the ACG 2024 meeting is a significant milestone in the development of potential therapies for chronic liver disease-related pruritus. The promising results of this trial highlight the company’s dedication to advancing innovative treatments in inflammation and immunology, with the potential to positively impact both individual patients and global healthcare.
